• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » OHRP Weighs in on Protecting Research Participants During COVID-19 Pandemic

OHRP Weighs in on Protecting Research Participants During COVID-19 Pandemic

April 13, 2020

Sponsors and investigators conducting federally funded research do not need IRB approval for actions taken in response to the threat of COVID-19 as long as those actions are for public health or clinical treatments purposes rather than research, according to a new guidance from the Office for Human Research Protections (OHRP).

Investigators also are permitted to make changes to approved research plans without prior IRB approval when responding to an immediate threat to patients.

OHRP’s guidance provides recommendations for following the patient protection requirements in the Common Rule (45 CFR 46) when a federally funded research project is impacted by the virus, including releasing identifiable information about research subjects to a public health authority. Investigators must comply with federal, state and local laws that require disclosure of a research subject’s positive COVID-19 test results, the guidance says, adding that the subject should be informed of the disclosure.

OHRP also says the recently issued FDA guidance on conducting trials during the pandemic is consistent with the Common Rule’s patient protection requirements and may be followed by investigators whether or not they are conducting FDA-regulated research.

To read the guidance, click here: https://bit.ly/3e9FVCB.

COVID-19
    • Related Directories

      Olumiant (baricitinib)

      Veklury (remdesivir)

      Comirnaty (COVID-19 Vaccine, mRNA)

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing